CENTER FOR DRUG EVALUATION AND RESEARCH

DIVISION of
DRUG INFORMATION

Your source for the latest drug information. Know the moment it happens.

​

FDA Warns about Liver Injury with Use of Veozah (fezolinetant) for Menopausal Hot Flashes

Today, the U.S. Food and Drug Administration released a Drug Safety Communication warning that Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, can cause rare but serious liver injury.

Patients should stop taking Veozah immediately and seek medical attention, including liver blood testing, if they experience signs and symptoms that suggest liver problems such as feeling more tired than usual; nausea; vomiting; unusual itching; light-colored stools; yellowing of the eyes or skin, called jaundice; dark urine; swelling in the stomach area, called the abdomen; or pain in the right upper abdomen.

If you are taking Veozah or want to learn about whether Veozah may be right for you, talk to your health care professional about the risks and benefits of receiving Veozah and discuss any questions or concerns you may have, including about possible alternative treatments. For more information, please visit FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for menopausal hot flashes.

Veozah is a nonhormonal prescription medicine approved in May 2023 to reduce the frequency and severity of moderate to severe hot flashes caused by menopause.

This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov.